Physician

Ghulam Hossein Kashef, MD

According to 2025 Medicare claims, Ghulam Kashef, MD (NPI: 1679662688) practices hematology/oncology in the Las Vegas-Henderson-North Las Vegas, NV market, with the plurality of this provider's patient population coming from Clark, NV. This provider's primary affiliated billing organization is ALLISON CURTIS KINGSLEY MEOZ MICHAEL & SANCHEZ PC (NPI: 1598770471; TIN: 88-0350180) and primary practice location at 89052-3908.

Kashef's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 856 traditional Medicare patients, billed 233,008 HCPCS/CPT codes, and received $4,517,228 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 959 prescription claims across 171 beneficiaries totaling $1,852,292 in drug costs, led by Calquence (Acalabrutinib Maleate). DME data shows 44 claims. Open Payments data shows 171 records totaling $2,939. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,603,160 to $4,517,228. Similarly, Part D prescription costs have risen steadily, from $568,195 to $1,852,292. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	808	156,793	$1,603,160
2016	962	225,082	$2,017,529
2017	897	217,828	$2,546,525
2018	1,029	312,286	$3,354,028
2019	1,014	325,215	$3,678,178
2020	877	242,111	$3,707,810
2021	941	301,693	$5,659,678
2022	890	271,899	$5,285,358
2023	832	235,810	$4,937,117
2024	856	233,008	$4,517,228

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	106	620	$568,195
2016	157	857	$953,714
2017	168	934	$1,547,701
2018	173	969	$1,143,052
2019	174	952	$1,152,318
2020	166	908	$1,402,863
2021	179	905	$1,862,418
2022	166	873	$1,524,292
2023	157	961	$1,960,039
2024	171	959	$1,852,292

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	89	$21,432
2016	N/R	18	$1,525
2017	N/R	13	$245
2018	N/R	33	$5,218
2019	N/R	39	$5,907
2020	N/R	78	$6,331
2021	N/R	30	$2,420
2022	N/R	64	$2,609
2023	N/R	N/R	N/R
2024	N/R	44	$1,254

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	284	737	$96
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	234	333	$66
80053	Blood test, comprehensive group of blood chemicals	340	807	$10
36415	Insertion of needle into vein for collection of blood sample	449	1,503	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	447	1,582	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Calquence	Acalabrutinib Maleate	35	960	$474,714
Pomalyst	Pomalidomide	23	644	$401,199
Imbruvica	Ibrutinib	16	454	$229,525
Tasigna	Nilotinib Hcl	15	420	$66,468
Xarelto	Rivaroxaban	62	2,700	$48,401

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	19	$865
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$226
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$163

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	171	$2,939	Daiichi Sankyo Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ghulam Hossein Kashef, MD?

Tedicare shows public-source Medicare data for Ghulam Hossein Kashef, MD (NPI 1679662688), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ghulam Hossein Kashef, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ghulam Hossein Kashef, MD?

Ghulam Hossein Kashef, MD is linked to ALLISON CURTIS KINGSLEY MEOZ MICHAEL & SANCHEZ PC (billing NPI 1598770471) in the available physician profile data.

Does Ghulam Hossein Kashef, MD have Open Payments data?

Ghulam Hossein Kashef, MD has 171 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.